AF631
antibody from R&D Systems
Targeting: TNFRSF10B
CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB
Antibody data
- Antibody Data
- Antigen structure
- References [27]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF631 - Provider product page
- Provider
- R&D Systems
- Product name
- Human TRAIL R2/TNFRSF10B Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Detects human TRAIL R2/TNFRSF10B in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross-reactivity with recombinant human (rh) TRAIL R1 and rhTRAIL R4 is observed, and less than 1% cross-reactivity with rhTRAIL R3 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
Q6FH58
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells.
Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.
Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Liapis V, Zysk A, DeNichilo M, Zinonos I, Hay S, Panagopoulos V, Shoubridge A, Difelice C, Ponomarev V, Ingman W, Atkins GJ, Findlay DM, Zannettino ACW, Evdokiou A
Cancer medicine 2017 Sep;6(9):2164-2176
Cancer medicine 2017 Sep;6(9):2164-2176
Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
Shlyakhtina Y, Pavet V, Gronemeyer H
Cell death & disease 2017 Aug 31;8(8):e3025
Cell death & disease 2017 Aug 31;8(8):e3025
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM, Woo JS, Jeong CH, Ryu CH, Jang JD, Jeun SS
Stem cells translational medicine 2014 Feb;3(2):172-82
Stem cells translational medicine 2014 Feb;3(2):172-82
Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells.
Park SJ, Sohn HY, Yoon J, Park SI
Cellular signalling 2009 Oct;21(10):1495-503
Cellular signalling 2009 Oct;21(10):1495-503
Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH
The Biochemical journal 2009 Apr 28;420(1):73-81
The Biochemical journal 2009 Apr 28;420(1):73-81
Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH
Biochemical pharmacology 2009 Apr 15;77(8):1328-36
Biochemical pharmacology 2009 Apr 15;77(8):1328-36
TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
Wu CH, Kao CH, Safa AR
Human gene therapy 2008 Jul;19(7):731-43
Human gene therapy 2008 Jul;19(7):731-43
Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS
Cancer research 2008 Jan 1;68(1):266-75
Cancer research 2008 Jan 1;68(1):266-75
Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M
International journal of oncology 2008 Aug;33(2):381-8
International journal of oncology 2008 Aug;33(2):381-8
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M
International journal of oncology 2007 Dec;31(6):1391-402
International journal of oncology 2007 Dec;31(6):1391-402
Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
Lane D, Côté M, Grondin R, Couture MC, Piché A
Molecular cancer therapeutics 2006 Mar;5(3):509-21
Molecular cancer therapeutics 2006 Mar;5(3):509-21
P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR
Biochemical pharmacology 2006 Jul 28;72(3):293-307
Biochemical pharmacology 2006 Jul 28;72(3):293-307
Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
Roux S, Lambert-Comeau P, Saint-Pierre C, Lépine M, Sawan B, Parent JL
Biochemical and biophysical research communications 2005 Jul 22;333(1):42-50
Biochemical and biophysical research communications 2005 Jul 22;333(1):42-50
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.
Morel J, Audo R, Hahne M, Combe B
The Journal of biological chemistry 2005 Apr 22;280(16):15709-18
The Journal of biological chemistry 2005 Apr 22;280(16):15709-18
Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death.
Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A, Colombo A, Parati E, Peschle C, De Maria R
The Journal of experimental medicine 2004 Nov 15;200(10):1257-66
The Journal of experimental medicine 2004 Nov 15;200(10):1257-66
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
Ruiz de Almodóvar C, Ruiz-Ruiz C, Rodríguez A, Ortiz-Ferrón G, Redondo JM, López-Rivas A
The Journal of biological chemistry 2004 Feb 6;279(6):4093-101
The Journal of biological chemistry 2004 Feb 6;279(6):4093-101
Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
Chopin V, Slomianny C, Hondermarck H, Le Bourhis X
Experimental cell research 2004 Aug 15;298(2):560-73
Experimental cell research 2004 Aug 15;298(2):560-73
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
Voelkel-Johnson C
Cancer biology & therapy 2003 May-Jun;2(3):283-90
Cancer biology & therapy 2003 May-Jun;2(3):283-90
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
Voelkel-Johnson C
Cancer biology & therapy 2003 May-Jun;2(3):283-90
Cancer biology & therapy 2003 May-Jun;2(3):283-90
Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K
Oncogene 2003 Mar 20;22(11):1653-62
Oncogene 2003 Mar 20;22(11):1653-62
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Mouzakiti A, Packham G
British journal of haematology 2003 Jul;122(1):61-9
British journal of haematology 2003 Jul;122(1):61-9
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Mouzakiti A, Packham G
British journal of haematology 2003 Jul;122(1):61-9
British journal of haematology 2003 Jul;122(1):61-9
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, Capitani S, Zauli G
Journal of leukocyte biology 2003 Aug;74(2):223-32
Journal of leukocyte biology 2003 Aug;74(2):223-32
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, Capitani S, Zauli G
Journal of leukocyte biology 2003 Aug;74(2):223-32
Journal of leukocyte biology 2003 Aug;74(2):223-32
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P
Circulation research 2003 Apr 18;92(7):732-40
Circulation research 2003 Apr 18;92(7):732-40
Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Jr
Cell death and differentiation 2002 Mar;9(3):274-86
Cell death and differentiation 2002 Mar;9(3):274-86
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC
Oncogene 2002 Aug 22;21(37):5673-83
Oncogene 2002 Aug 22;21(37):5673-83
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Detection of Human TRAIL R2/TNFRSF10B by Western Blot. Western blot shows lysates of HepG2 human hepatocellular carcinoma cell line. PVDF membrane was probed with 1 µg/mL of Human TRAIL R2/TNFRSF10B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF631) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for TRAIL R2/TNFRSF10B at approximately 45 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.